Science Explorer Back to mapMap
Discussion
Topic · Molecular Biology

Renal and related cancers

Renal and related cancers is a research topic within Molecular Biology. Science Explorer counts 38k research works in it since 1950. 10.0% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the molecular mechanisms underlying kidney development, including the use of kidney organoids derived from pluripotent stem cells to model nephrogenesis and injury. It also delves into the role of specific genes such as WT1, the signaling pathways like GDNF/Ret, and the cellular processes involved in branching morphogenesis. Additionally, it covers topics related to congenital anomalies, podocyte development, and Wilms tumor, providing a comprehensive understanding of kidney development and disease.

  • Kidney Organoids
  • Nephrogenesis
  • WT1 Gene
  • Renal Progenitors
  • Branching Morphogenesis
  • GDNF/Ret Signaling
  • Pluripotent Stem Cells
  • Congenital Anomalies
  • Podocyte Development
  • Wilms Tumor
Research works
38k
fractional, since 1950
In the world top 10%
3.8k
per year above
Top-10% rate
10.0%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-4%
the tick is no change
Largest producer
United States
34% of the 10 largest, 2022-now
Renal and related cancers

Which countries lead Renal and related cancers research?

By volume, the United States and China publish the most (1.5k and 1.2k works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.5k works
  2. 2 China 1.2k works
  3. 3 Japan 340 works
  4. 4 India 284 works
  5. 5 Germany 248 works
  6. 6 United Kingdom 221 works
  7. 7 Italy 214 works
  8. 8 France 159 works
  9. 9 Canada 126 works
  10. 10 South Korea 116 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 33.9%China: 26.9%Japan: 7.8%India: 6.5%6 others listed: 24.8%34%largest
United States1,481 · 33.9%China1,174 · 26.9%Japan340 · 7.8%India284 · 6.5%6 others listed1,083 · 24.8%

Shares of the rows listed above, not of the whole node.

Which institutions lead Renal and related cancers research?

By volume in 2022-now, Harvard University publishes the most Renal and related cancers research, followed by Shanghai Jiao Tong University and National Institutes of Health.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 83 works
  2. 2 Shanghai Jiao Tong UniversityChina 46 works
  3. 3 National Institutes of HealthUnited States 36 works
  4. 4 Mayo ClinicUnited States 36 works
  5. 5 Peking UniversityChina 35 works
  6. 6 Zhejiang UniversityChina 33 works
  7. 7 Sun Yat-sen UniversityChina 33 works
  8. 8 All India Institute of Medical SciencesIndia 33 works
  9. 9 Sichuan UniversityChina 31 works
  10. 10 Nanjing Medical UniversityChina 30 works

Who are the leading researchers in Renal and related cancers?

The most-cited researchers publishing on Renal and related cancers include Eric S. Lander, George Davey Smith and Richard M. Durbin.

  1. 1 Eric S. Lander United States 524k citations
  2. 2 George Davey Smith United Kingdom 435k citations
  3. 3 Richard M. Durbin United Kingdom 410k citations
  4. 4 Mark J. Daly United States 403k citations
  5. 5 Stacey L. Gabriel United States 402k citations
  6. 6 Bert Vogelstein United States 373k citations
  7. 7 Gad A. Getz United States 364k citations
  8. 8 Elaine R. Mardis United States 346k citations
  9. 9 Hermann Brenner Germany 343k citations
  10. 10 Jun Wang China 340k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Renal and related cancers?

The most cited paper in Renal and related cancers is "Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors" (Kazutoshi Takahashi, Shinya Yamanaka, 2006), with 26,957 citations. Next come "Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells" (10,385) and "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer" (7,190).

Most cited papers
#PaperReleasedCitations
1 Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors Kazutoshi Takahashi, Shinya Yamanaka · Cell Open access Aug 2006 26,957
2 Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells Junying Yu, Maxim A. Vodyanik, Kim Smuga-Otto et al. · Science 20 Nov 2007 10,385
3 Specific Association of Human Telomerase Activity with Immortal Cells and Cancer Nam W. Kim, Mieczyslaw A. Piatyszek, Karen R. Prowse et al. · Science 23 Dec 1994 7,190
4 Analysis of nanoparticle delivery to tumours Stefan Wilhelm, Anthony J. Tavares, Qin Dai et al. · Nature Reviews Materials ReviewOpen access 26 Apr 2016 5,120
5 Viable offspring derived from fetal and adult mammalian cells I. Wilmut, Angelika Schnieke, J. McWhir et al. · Nature Feb 1997 4,968
All 99 most cited papers, with filters and sorting

Where is Renal and related cancers research done?

The largest centres of Renal and related cancers research in 2022-now are Beijing (China), Shanghai (China), Tokyo (Japan) and Guangzhou (China). Among places with at least 20 works in it, it is an unusually large share of all research in Memphis, Cincinnati and Dallas.

Largest cities, 2022-now

  1. 1 BeijingChina 144 works
  2. 2 ShanghaiChina 117 works
  3. 3 TokyoJapan 91 works
  4. 4 GuangzhouChina 90 works
  5. 5 New YorkUnited States 75 works
  6. 6 LondonUnited Kingdom 72 works
  7. 7 ParisFrance 72 works
  8. 8 BostonUnited States 71 works
  9. 9 SeoulSouth Korea 55 works
  10. 10 HangzhouChina 55 works

Where it is the local speciality

  1. MemphisUS · 20.3 works7.3×
  2. CincinnatiUS · 25.0 works5.6×
  3. DallasUS · 22.9 works5.1×
  4. BethesdaUS · 34.8 works5.1×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Renal and related cancers than the world average.

See Renal and related cancers on the map

Where is the best place to study Renal and related cancers?

Among universities, judged by research, Harvard University, Chinese University of Hong Kong and University of Cambridge score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 18.51%fractional works in this field (log) →share of work in the world top 10% →Chinese University o…Medical University o…University of Cambri…Harvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 78.518.7%5.1×83 -2.2%
2Chinese University of Hong KongChina 68.129.1%2.8×10 +73.6%
3University of CambridgeUnited Kingdom 58.319.5%2.6×16 -5.9%
4Medical University of ViennaAustria 57.926.4%5.9×10 +59.2%
5Zhejiang UniversityChina 57.717.6%2.5×34 +20.9%
6University of Southern CaliforniaUnited States 57.115.2%6.1×26 +50.7%
7University of PennsylvaniaUnited States 57.114.6%4.0×22 +24.2%
8Johns Hopkins UniversityUnited States 56.812.1%3.7×29 +17.4%
9University of CincinnatiUnited States 56.816.4%7.8×23 -1.5%
10Sichuan UniversityChina 54.215.5%2.8×32 +98.3%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Renal and related cancers, country by country

Is Renal and related cancers research growing?

Output in 2022-2025 was 4% lower than in 2018-2021, peaking in 2022.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Renal and related cancers as a percentage of every work published that year, 0.025% in 2024.

still counting0.020%0.040%0.060%Renal and related cancers0.022% in 202519801990200020102020

Fractional works of Renal and related cancers over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Renal and related cancers10.1% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Renal and related cancers. Posts are plain text and can be reported.